Nucleoside compounds for treating viral infections
3 Assignments
0 Petitions
Accused Products
Abstract
Disclosed are compounds, compositions and methods for treating viral infections caused by a flaviviridae family virus, such as hepatitis C virus. Such compounds are represented by Formula I as follows:
wherein, each of R, Y, W, W1 and W2 are as defined herein.
-
Citations
24 Claims
- 1. A compound of formula Ia:
-
2. A compound selected from the group consisting of:
-
7-(2′
-C-methyl-β
-D-ribofuranosyl)-4-amino-5-(ethen-1-yl)-pyrrolo[2,3-d]pyrimidine;7-(2′
-C-methyl-β
-D-ribofuranosyl)-4-amino-5-(2-cis-methoxy-ethen-1-yl)-pyrrolo[2,3-d]pyrimidine;7-(2′
-C-methyl-5′
-monophospho-β
-D-ribofuranosyl)-4-amino-5-(ethen-1-yl)-pyrrolo[2,3-d]pyrimidine;7-(2′
-C-methyl-5′
-diphospho-β
-D-ribofuranosyl)-4-amino-5-(ethen-1-yl)-pyrrolo[2,3-d]pyrimidine;7-(2′
-C-methyl-5′
-triphospho-β
-D-ribofuranosyl)-4-amino-5-(ethen-1-yl)-pyrrolo[2,3-d]pyrimidine;7-(2′
-C-methyl-5′
-monophospho-β
-D-ribofuranosyl)-4-amino-5-(2-cis-methoxy-ethen-1-yl)-pyrrolo[2,3-d]pyrimidine;7-(2′
-C-methyl-5′
-diphospho-β
-D-ribofuranosyl)-4-amino-5-(2-cis-methoxy-ethen-1-yl)-pyrrolo[2,3-d]pyrimidine; and7-(2′
-C-methyl-5′
-triphospho-β
-D-ribofuranosyl)-4-amino-5-(2-cis-methoxy-ethen-1-yl)-pyrrolo[2,3-d]pyrimidine;or pharmaceutically acceptable salts or partial salts thereof.
-
- 5. A compound of formula II:
-
6. A compound selected from the group consisting of:
-
7-(2′
-C-methyl-β
-D-ribofuranosyl)-4-amino-5-(2-carboxyethyn-1-yl)-pyrrolo[2,3-d]pyrimidine;7-(2′
-C-methyl-5′
-phospho-β
-D-ribofuranosyl)-4-amino-5-(2-carboxyethyn-1-yl)-pyrrolo[2,3-d]pyrimidine;7-(2′
-C-methyl-5′
-diphospho-β
-D-ribofuranosyl)-4-amino-5-(2-carboxyethyn-1-yl)-pyrrolo[2,3-d]pyrimidine; and7-(2′
-C-methyl-5′
-triphospho-β
-D-ribofuranosyl)-4-amino-5-(2-carboxyethyn-1-yl)-pyrrolo[2,3-d]pyrimidine;or pharmaceutically acceptable salts or partial salts thereof.
-
-
9. A compound of formula III:
-
10. A compound selected from the group consisting of:
-
7-(2′
-C-methyl-β
-D-ribofuranosyl)-4-amino-5-[(ethyl 2-carboxyl)ethyn-1-yl]-pyrrolo[2,3-d]pyrimidine;7-(2′
-C-methyl-β
-D-ribofuranosyl)-4-amino-5-[(methyl 2-carboxyl)ethyn-1-yl]-pyrrolo[2,3-d]pyrimidine;7-(2′
-C-methyl-5′
-phospho-β
-D-ribofuranosyl)-4-amino-5-[(ethyl 2-carboxyl)ethyn-1-yl]-pyrrolo[2,3-d]pyrimidine;7-(2′
-C-methyl-5′
-phospho-β
-D-ribofuranosyl)-4-amino-5-[(methyl 2-carboxyl)ethyn-1-yl]-pyrrolo[2,3-d]pyrimidine;7-(2′
-C-methyl-5′
-diphospho-β
-D-ribofuranosyl)-4-amino-5-[(ethyl 2-carboxyl)ethyn-1-yl]-pyrrolo[2,3-d]pyrimidine;7-(2′
-C-methyl-5′
-diphospho-β
-D-ribofuranosyl)-4-amino-5-[(methyl 2-carboxyl)ethyn-1-yl]-pyrrolo[2,3-d]pyrimidine;7-(2′
-C-methyl-5′
-triphospho-β
-D-ribofuranosyl)-4-amino-5-[(ethyl 2-carboxyl)ethyn-1-yl]-pyrrolo[2,3-d]pyrimidine; and7-(2′
-C-methyl-5′
-triphospho-β
-D-ribofuranosyl)-4-amino-5-[(methyl 2-carboxyl)ethyn-1-yl]-pyrrolo[2,3-d]pyrimidine;or pharmaceutically acceptable salts or partial salts thereof. - View Dependent Claims (11, 12)
-
- 13. A compound of formula V:
-
14. A compound selected from the group consisting of:
-
7-(2′
-C-methyl-β
-D-ribofuranosyl)-4-amino-5-(2-phenylethyn-1-yl)-pyrrolo[2,3-d]pyrimidine;7-(2′
-C-methyl-β
-D-ribofuranosyl)-4-amino-5-(2-(4-fluorophenyl)ethyn-1-yl)-pyrrolo[2,3-d]pyrimidine;7-(2′
-C-methyl-β
-D-ribofuranosyl)-4-amino-5-(2-(4-methylphenyl)ethyn-1-yl)-pyrrolo[2,3-d]pyrimidine;7-(2′
-C-methyl-5′
-phospho-β
-D-ribofuranosyl)-4-amino-5-(2-phenylethyn-1-yl)-pyrrolo[2,3-d]pyrimidine;7-(2′
-C-methyl-5′
-phospho-β
-D-ribofuranosyl)-4-amino-5-(2-(4-fluorophenyl)ethyn-1-yl)-pyrrolo[2,3-d]pyrimidine;7-(2′
-C-methyl-5′
-phospho-β
-D-ribofuranosyl)-4-amino-5-(2-(4-methylphenyl)ethyn-1-yl)-pyrrolo[2,3-d]pyrimidine;7-(2′
-C-methyl-5′
-diphospho-β
-D-ribofuranosyl)-4-amino-5-(2-phenylethyn-1-yl)-pyrrolo[2,3-d]pyrimidine;7-(2′
-C-methyl-5′
-diphospho-β
-D-ribofuranosyl)-4-amino-5-(2-(4-fluorophenyl)ethyn-1-yl)-pyrrolo[2,3-d]pyrimidine;7-(2′
-C-methyl-5′
-diphosphol-β
-D-ribofuranosyl)-4-amino-5-(2-(4-methylphenyl)ethyn-1-yl)-pyrrolo[2,3-d]pyrimidine;7-(2′
-C-methyl-5′
-triphosphol-β
-D-ribofaranosyl)-4-amino-5-(2-phenylethyn-1-yl)-pyrrolo[2,3-d]pyrimidine;7-(2′
-C-methyl-5′
-triphosphol-β
-D-ribofuranosyl)-4-amino-5-(2-(4-fluorophenyl)ethyn-1-yl)-pyrrolo[2,3-d]pyrimidine; and7-(2′
-C-methyl-5′
-triphosphol-β
-D-ribofuranosyl)-4-amino-5-(2-(4-methylphenyl)ethyn-1-yl)-pyrrolo[2,3-d]pyrimidine;or pharmaceutically acceptable salts or partial salts thereof.
-
-
17. 7-(2′
- -C-methyl-β
-D-ribofuranosyl)-4-amino-5-(ethen-1-yl)-pyrrolo[2,3-d]pyrimidine or a pharmaceutically acceptable salt or partial salt thereof.
- -C-methyl-β
-
18. 7-(2′
- -C-methyl-β
-D-ribofuranosyl)-4-amino-5-(2-cis-methoxy-ethen-1-yl)-pyrrolo[2,3-d]pyrimidine or a pharmaceutically acceptable salt or partial salt thereof.
- -C-methyl-β
-
19. 7-(2′
- -C-methyl-β
-D-ribofuranosyl)-4-amino-5-(2-phenylethyn-1-yl)-pyrrolo[2,3-d]pyrimidine or a pharmaceutically acceptable salt or partial salt thereof.
- -C-methyl-β
-
20. 7-(2′
- -C-methyl-β
-D-ribofuranosyl)-4-amino-5-(2-(4-fluorophenyl)ethyn-1-yl)-pyrrolo[2,3-d]pyrimidine or a pharmaceutically acceptable salt or partial salt thereof.
- -C-methyl-β
-
21. 7-(2′
- -C-methyl-β
-D-ribofuranosyl)-4-amino-5-(2-(4-methylphenyl)ethyn-1-yl)-pyrrolo[2,3-d]pyrimidine or a pharmaceutically acceptable salt or partial salt thereof.
- -C-methyl-β
-
22. 7-(2′
- -C-methyl-β
-D-ribofuranosyl)-4-amino-5-(2-carboxyethyn-1-yl)-pyrrolo[2,3-d]pyrimidine or a pharmaceutically acceptable salt or partial salt thereof.
- -C-methyl-β
-
23. 7-(2′
- -C-methyl-β
-D-ribofuranosyl)-4-amino-5-[(ethyl 2-carboxyl)ethyn-1-yl]-pyrrolo[2,3-d]pyrimidine or a pharmaceutically acceptable salt or partial salt thereof.
- -C-methyl-β
-
24. 7-(2′
- -C-methyl-β
-D-ribofuranosyl)-4-amino-5-[(methyl 2-carboxyl)ethyn-1-yl]-pyrrolo[2,3-d]pyrimidine or a pharmaceutically acceptable salt or partial salt thereof.
- -C-methyl-β
Specification